300463 Maccura Biotechnology
- 14.01
- +0.01+0.07%
Maccura Biotechnology News
Maccura Biotechnology Gets Nod to Register Rheumatoid Arthritis Kit
maccura biotechnology (300463.SZ): obtained the product registration certificate for rheumatoid arthritis indicators detection kit
On November 14th, Maccura Biotechnology (300463.SZ) announced that the company recently received the "Medical Instruments Registration Certificate (In Vitro Diagnostic Reagents)" issued by the Sichuan Provincial Drug Administration. The product named Rheumatoid Factor Determination Reagent Kit (Latex Immunoassay Turbidimetry) is used for quantitative measurement of rheumatoid factors in human serum or plasma outside the body.
maccura biotechnology (300463.SZ): cumulatively repurchased 0.65% of shares
On November 1st, Maccura Biotechnology (300463.SZ) announced that, as of October 31, 2024, the company has repurchased a total of 3,958,000 shares through a repurchase dedicated securities account in a centralized competitive trading manner, accounting for 0.65% of the company's current total share capital. The fill price was 12.64 yuan per share, with the highest fill price at 14.48 yuan per share, and the lowest fill price at 10.91 yuan per share. The total amount paid was 50,022,021.82 yuan (excluding transaction fees). This repurchase is in compliance with the company's share repurchase plan and relevant laws and regulations.
Earnings Troubles May Signal Larger Issues for Maccura BiotechnologyLtd (SZSE:300463) Shareholders
Maccura Biotechnology (300463.SZ): It is expected that in the first half of next year, C2000 will be promoted through a production line format.
Gelonghui, October 24th - maccura biotechnology (300463.SZ) stated at the investor relations event that the C2000 and C1000 models have been released, with C1000 just entering the market and Max products not yet widely introduced. It is expected that the C2000 will be promoted through the pipeline form in the first half of next year.
Mike Biotech: Report for the third quarter of 2024
maccura biotechnology (300463.SZ) intends to sell 60% of its equity in Inner Mongolia Maccura for 23.9401 million yuan
maccura biotechnology (300463.SZ) announced that the company plans to sell its stake at an initial trading price of 23.9401 million yuan...
Maccura Biotechnology (300463.SZ): Intends to transfer 60% equity of Inner Mongolia Maccura for 23.9401 million yuan to Meishidian
On October 22, Maccura Biotechnology (300463.SZ) announced that, with the clear positioning of the company's global strategy and the changing market environment, in order to further focus on core business, optimize resource allocation, enhance the company's market competitiveness and operational quality, and accelerate the adjustment of regional direct sales and distribution businesses. Maccura Biotechnology Co., Ltd. intends to transfer 60% of the equity of its holding subsidiary Inner Mongolia Maccura Biotechnology Co., Ltd. (hereinafter referred to as 'Inner Mongolia Maccura') to Meishidian at an initial trading price of RMB 23.9401 million. After this equity transfer is completed, the company will no longer hold equity in Inner Mongolia Maccura, and
Maccura Biotechnology (300463.SZ): net income in the third quarter was 79.6466 million yuan, a year-on-year decrease of 15.13%.
GeneQuantum reported its financial results for the third quarter of 2024 on October 22. During the reporting period, the revenue was 0.669 billion yuan, a decrease of 8.94% year-on-year; the net income attributable to the shareholders of the listed company was 79.6466 million yuan, a decrease of 15.13% year-on-year; the net income attributable to the shareholders of the listed company, excluding non-recurring gains and losses, was 93.0702 million yuan, a decrease of 3.95% year-on-year; and the basic earnings per share was 0.1302 yuan.
maccura biotechnology (300463.SZ): The new product gastric function quality control product has obtained the product registration certificate
On October 14, Gelonghui reported that Maccura Biotechnology (300463.SZ) announced that it recently received the Medical Instruments Registration Certificate (In Vitro Diagnostic Reagents) issued by the Sichuan Provincial Drug Administration, with the product name as Gastric Function Quality Control Product. The Gastric Function Quality Control Product is a new quality control product of the company's immune platform, mainly used for quality control of the company's PGI, PGII, and G-17 projects. The new product's registration certificate further enriches the company's product project menu, helps enhance the company's overall market competitiveness, and will have a positive impact on market expansion and the company's future operation.
It's A Story Of Risk Vs Reward With Maccura Biotechnology Co.Ltd (SZSE:300463)
Guosen Securities: After the centralized procurement of IVD, the industry landscape has changed, and the assembly line has become a battleground.
In the environment of centralized procurement, having TLA products with low cost and high quality will become the core competitiveness of IVD companies.
Maccura Biotechnology (300463.SZ) and its subsidiaries have obtained multiple medical instruments registration certificates.
Maccura Biotechnology (300463.SZ) announced that the company and its wholly-owned subsidiary Maccura Medical Electronics Co., Ltd. (abbreviated...
Maccura Biotechnology (300463.SZ): The company has been paying dividends every year since its listing, with a cumulative dividend payout of 1.214 billion yuan.
Gelonghui, September 4th, maccura biotechnology (300463.SZ) stated on the investor interaction platform that the company was listed on the A-share market in 2015, with a total IPO fundraising amount of 1.049 billion yuan. Since its listing, the company has continued to pay dividends every year. The proportion of profits distributed in cash each year has gradually increased from 20% to 30%, with a cumulative dividend payment of 1.214 billion yuan. In February 2022, a private placement was carried out with an actual total fundraising amount of 1.574 billion yuan. In accordance with the "Shareholder Dividend Return Plan for the Next Three Years (2023-2025)", the company plans to distribute dividends to shareholders each year.
Maccura Biotechnology (300463.SZ): has repurchased 0.48% of shares.
On September 2, Maccura Biotechnology (300463.SZ) announced that as of August 31, 2024, the company has repurchased a total of 2,954,300 shares of the company's stock through a dedicated securities account for centralized bidding trading, accounting for 0.48% of the company's current total share capital. The average transaction price was 12.13 yuan per share, with a highest transaction price of 13.23 yuan per share and a lowest transaction price of 10.91 yuan per share. The total amount paid was 35.8281 million yuan (excluding transaction fees).
Are Maccura Biotechnology Co.Ltd's (SZSE:300463) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
Maccura Biotechnology (300463.SZ): Dihydrotestosterone Sulfate Reagent Kit obtained product registration certificate.
On August 23, Maccura Biotechnology (300463.SZ) announced that the company has recently received the Medical Device Registration Certificate (In Vitro Diagnostic Reagent) issued by the Sichuan Provincial Drug Administration. The product is called Dehydroepiandrosterone Sulfate Determination Reagent Kit (Direct Chemiluminescence Method). This product is used for the quantitative determination of dehydroepiandrosterone sulfate in human serum or plasma samples. The Dehydroepiandrosterone Sulfate Determination Reagent Kit (Direct Chemiluminescence Method) is mainly used in clinical practice to evaluate the level of adrenal secretion of androgens. The quantitative detection of dehydroepiandrosterone sulfate is commonly used in adrenal hyperplasia, polycystic ovary syndrome, and female androgen disorders.
Maccura Biotechnology (300463.SZ): Obtained product registration certificates for two new products.
Maccura Biotechnology (300463.SZ) announced on August 13th that the company has recently received the Medical Device Registration Certificate (In Vitro Diagnostic Reagents) issued by the National Medical Products Administration. The products that have obtained product registration certificates are cytomegalovirus IgM antibody detection reagent kit (direct chemiluminescence method) and herpes simplex virus type 2 IgM antibody detection test kit (direct chemiluminescence method). Cytomegalovirus IgG antibody detection reagent kit (direct chemiluminescence method), as a pathogen antibody detection test kit, is currently mainly used for auxiliary diagnosis of cytomegalovirus infection. Herpes simplex virus type 2 IgM antibody detection test.
We Think Maccura BiotechnologyLtd (SZSE:300463) Can Stay On Top Of Its Debt
Maccura Biotechnology: Half-year report for the year 2024.
Analysis
Price Target
No Data
No Data